|
| |
| | Patent 4725668: Process for transforming teicoplanin factor A.sub.2 component 1 into teicoplanin factor A.sub.2, ... |
 | | As it is appreciated by those skilled in the art, it is very difficult to conduct any selective process on a structurally complex substrate like the present ones in view of the presence of a variety of different functional groups which may be altered at the reaction conditions. | | | Teicoplanin A.sub.2 factor 1 is a white amorphous powder that upon heating begins to darken at about 220.degree. | | | Teicoplanin A.sub.2 factor 3 is a white amorphous powder that upon heating begins to decompose at 205.degree. |
|
http://www.freepatentsonline.com/4725668.html
|
|
| |
| | The WorldWide Intensivist: A brief review of Teicoplanin |
| | The looming spectre of vancomycin (and/or teicoplanin) resistance should encourage us to be careful and not use either drug recklessly. | | | In several clinical circumstances, empiric treatment with teicoplanin is extremely effective. | | | Relatively few studies have compared clinical efficacy of vancomycin with that of teicoplanin. |
|
http://www.anaesthetist.com/icu/manage/drugs/infect/teico.htm
|
|
| |
| | Patent 5085990: Teicoplanin-like derivatives |
| | Their respective ratios in the teicoplanin complex can vary according to the fermentation conditions and the precursors added to the fermentation medium as described in the E.P.A. publication No. 204179. | | | Therefore, the separation and recovery of the new compounds from the fermentation broth of mutant A-184 is much simpler and substantial amounts of the new teicoplanin-like derivatives can be obtained. | | | In particular, a strain of Actinoplanes teichomyceticus which is characterized with our internal code No. A-184 has proved to be a suitable producer of the above mentioned teicoplanin-like derivatives. |
|
http://www.freepatentsonline.com/5085990.html
|
|
| |
| | JPEN: Journal of Parenteral and Enteral Nutrition: Efficacy of antibiotic-lock technique with teicoplanin in ... |
| | The finding that the antibiotic-lock technique with teicoplanin is not highly effective in the treatment of catheter-related sepsis related to SE does not support the use of this drug for the antibiotic-lock technique. | | | Conclusions: In this study, the incidence of catheter-related sepsis was low and mostly related to SE. | | | Our results do not support the use of the teicoplanin antibiotic-lock technique in SE infections. |
|
http://findarticles.com/p/articles/mi_qa3762/is_200203/ai_n9038478
|
|
| |
| | eMJA: Robertson et al., Vancomycin and teicoplanin use in Victorian hospitals |
| | This study was conducted by the Victorian Drug Usage Evaluation Group, a multidisciplinary group that aims to promote and improve coordination of drug use evaluation activities as a means to improve drug use. | | | The aim of this study was to examine patterns of prescribing vancomycin and teicoplanin in Victorian hospitals in order to identify potential areas for targeted intervention to improve use of these antibiotics. | | | It is of critical importance for patient care and resource management that there is a conscious effort to preserve the utility of vancomycin and teicoplanin. |
|
http://www.mja.com.au/public/issues/171_3_020899/robertsn/robertsn.html
|
|
| |
| | [No title] |
| | Further experimental and clinical studies are needed to determine the impact of elevated MICs of teicoplanin against Staphylococcus epidermidis. | | | We selected 7 clinical strains of Staphylococcus epidermidis with MICs of teicoplanin ranging from 0.25 to 32 mg/L. Two ciprofloxacin-resistant mutants (strains 15657 and A1894) were respectively obtained from wild-type strains 7453 and 7318. | | | We aimed to assess the relation between the MIC and experimental in vivo efficacy of teicoplanin against Staphylococcus epidermidis. |
|
http://www.blackwellpublishing.com/isth2003/abstract.asp?id=37621
|
|
| |
| | Dharma Vira Heart Centre |
| | This study will be conducted on 100 consecutive patients undergoing various open heart surgical procedures in the department of Cardiac Surgery, Dharma Vira Heart Centre, Sir Ganga Ram Hospital, New Delhi. | | | Apart from the history, physical examination and routine open heart work up, the following investigations will be conducted on all patients specifically before open heart surgery. | | | The patients having hypersensitivity to Teicoplanin will be excluded. |
|
http://sgrh.com/dept/cardio.htm
|
|
| |
| | Efficacy and security of teicoplanin in the treatment of severe infections.. |
| | The tolerance was good, only one patient was taken out of the study due to rash probably related to the studied drug. | | | The clinical results obtained were: 65% cured, 35% improved, with a bacteriological eradication of 100%. | | | Efficacy and security of teicoplanin in the treatment of severe infections.. |
|
http://www.imbiomed.com/HG/Hgv58n1/english/Zhg51-02.html
|
|
| |
| | Targocid 200mg & 400mg , SPC from the eMC |
| | Teicoplanin does not readily penetrate into the cerebro-spinal fluid (CSF). | | | Repeated evaluation of the patients condition is essential. | | | Determination of teicoplanin serum concentrations may optimise therapy. |
|
http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=9110
|
|
| |
| | [No title] |
| | A first-generation cephalosporin should be continued for non methicillin-resistant staphylococci; vancomycin, clindamycin, or teicoplanin for methicillin-resistant staphylococci; and ampicillin for enterococci and streptococci (Figure 2). | | | The choice of antibiotics should take into consideration the clinical symptoms of the patient and the concerns in relation to emerging resistance to glycopeptides. | | | If the patients are receiving a first-generation cephalosporin and the organism is methicillin-resistant, the cephalosporin should be discontinued and therapy with a glycopeptide (e.g., vancomycin or teicoplanin) or clindamycin should be instituted. |
|
http://www.ispd.org/guidelines/articles/pdi206/warady.txt
|
|
| |
| | ICAAC: Linezolid Significantly Better than Teicoplanin in Patients with Bacteraemia |
| | Fifteen of 27 bacteraemia patients taking teicoplanin achieved a clinical success. | | | The percentage of patients with bacteraemia who achieved clinical success with linezolid exceeded 88 percent compared with 57 percent with teicoplanin. | | | In the subgroup of patients with bacteraemia, 23 of 26 linezolid patients achieved a successful outcome, and half of those patients were able to go on to oral treatment. |
|
http://www.docguide.com/dg.nsf/PrintPrint/B221FB451AB9EABB85256B270049913F
|
|
| |
| | Teicoplanin deacylation process and product - US Patent 5936074 |
| | Separation of the deacyl teicoplanin, and, if desired, purification, are carried out by conventional techniques. | | | CO which corresponds to a change in mass of -154 amu. | | | ECB deacylase can also be produced by recombinant techniques; see Appl. |
|
http://www.patentstorm.us/patents/5936074.html
|
|
| |
| | United States Patent Application: 0050080004 |
| | Presently, the most interesting glycopeptides are teicoplanin and vancomycin. | | | Variance in the response (=the total area of the five TA2 components) up to +/-3% was accepted. | | | A method of treating a microorganism infection in a patient, comprising administering the composition according to claim 16 to a patient. |
|
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=/netahtml/PTO/search-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=mathiesen.IN.&OS=IN/mathiesen&RS=IN/mathiesen
|
|
| |
| | Pharmacokinetics of Teicoplanin in Patients Undergoing Open Heart Surgery |
| | The purpose of this study was to investigate the pharmacokinetics of teicoplanin (TEIC) in patients undergoing open heart surgery. | | | Pharmacokinetics of Teicoplanin in Patients Undergoing Open Heart Surgery | | | We also attemped to define the optimum TEIC therapy protocol for prevention of perioperative infection and for treatment of staphylococcal endocarditis such as that caused by methicillin-resistant Staphylococcus aureus (MRSA). |
|
http://jscvs.umin.ac.jp/eng/journal/vol30-5/226.html
|
|
| |
| | ANTIBIOTIKA MONITOR - 6/03 Teicoplanin |
| | Somit kann festgehalten werden, dass Teicoplanin in Kombination mit Linezolid eine interessante Alternative bei der Therapie von schweren MRSA-Infektionen darstellen könnte. | | | Diese Resultate bestätigen die gute Wirkung von Teicoplanin als Kombinationspartner, das schon allein wegen seiner langen Halbwertszeit eine interessante Alternative zur herkömmlichen Therapie von MRSA-Infektionen darstellt. | | | Graninger W., Wenisch C., Wiesinger S., Menschik M., Karimi J., Presterl E.: "Experience with outpatient intravenous Teicoplanin therapy for chronic osteomyelitis." Eur. |
|
http://www.antibiotikamonitor.at/6_03/6_03_5.htm
|
|
| |
| | Karger Publishers |
| | Ampicillin, Gentamicin and Teicoplanin as Antimicrobial Therapy for Recurrent Streptococcus agalactiae and Enterococcus faecalis Endocarditis in an Intravenous Drug Abuser with HIV Infection | | | ampicillin, gentamicin and teicoplanin led to complete clinical and echocardiographical recovery. |
|
http://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowAbstract&ProduktNr=223834&Ausgabe=229249&ArtikelNr=71146
|
|
| |
| | CDC - Emergence of Vancomycin-Intermediate Staphylococcus aureus and S. sciuri, Greece |
| | The MIC of the strain for vancomycin was 8 µg/mL and for teicoplanin 16 µg/mL by the agar dilution method, and the result was confirmed by the E-test and the broth microdilution method. | | | To the Editor: Staphylococcal isolates with reduced susceptibility to glycopeptides, such as vancomycin and teicoplanin, are a serious public health problem because staphylococci frequently show multidrug resistance, and glycopeptides are the only remaining effective drugs. | | | The strain was also resistant to tobramycin, macrolides, tetracyclines, rifampicin, and fusidic acid, and had intermediate resistance to vancomycin (MIC 8 µg/mL) and teicoplanin (MIC 16 µg/mL) by all tested methods (agar dilution, broth microdilution, and E-test). |
|
http://www.cdc.gov/ncidod/eid/vol8no5/01-0387.htm
|
|
| |
| | eMJA: Ward et al, Treatment failure due to methicillin-resistant Staphylococcus aureus (MRSA) with reduced ... |
| | Our identification of hVISA may be the beginning of a new phase in the emergence of antibiotic resistance in Australia, when the glycopeptides vancomycin and teicoplanin will no longer be effective in some cases of MRSA infection. | | | Instead, attention should be focused on patients in whom glycopeptide therapy is failing, or those at increased risk of MRSA carriage and infection, such as patients undergoing haemodialysis or chronic ambulatory peritoneal dialysis. | | | The glycopeptides, vancomycin and, to a lesser extent, teicoplanin, are the mainstay of therapy for infections caused by methicillin-resistant Staphylococcus aureus (MRSA), |
|
http://www.mja.com.au/public/issues/175_09_051101/ward/ward.html
|
|
| |
| | Eurosurveillance Weekly 2000;4 (27): 06/07/2000 |
| | A prospective study of the outcome of patients infected with these strains is planned in order to assess their clinical impact. | | | For over 30 years vancomycin has been considered as the antibiotic of first choice for treatment of infections with methicillin resistant Staphylococcus aureus (MRSA). | | | Neither clinical nor epidemiological data allow us to suggest that the virulence of S. aureus with decreased or intermediate susceptibility to teicoplanin or vancomycin differs from that of other MRSA. |
|
http://www.eurosurveillance.org/ew/2000/000706.asp
|
|
| |
| | NEJM -- Staphylococcus aureus Infections |
| | As Dr. Conde suggests, teicoplanin was not mentioned because | | | are noted, the author does not mention teicoplanin. | | | Anti-gram-positive agents: what we have and what we would like. |
|
http://content.nejm.org/cgi/content/full/339/27/2025
|
|
| |
| | 2001 Volume 79 May (5 |
| | There is augmenting concern about the increased incidence of Staphylococcus spp strains with intermediate resistance to glycopeptides, as well as Enterococcus spp strains vancomycin resistant (VRE). | | | They differ in their pharmacokinetics, since teicoplanin may be administered both intravenously and intramuscularly, whereas vancomycin only intravenously, and due to the prolonged serum half-life (Ô½) of teicoplanin, compared to that of vancomycin. | | | Five phenotypes of VRE strains are reported: VanA with highly elevated minimal inhibitory concentrations (MICs) of vancomycin and teicoplanin is found in isolates of Enterococcus faecalis and Enterococcus faecium and is genetically transferred by the transposon Tn1546; VanB with highly elevated MICs of vancomycin and relatively lower of teicoplanin is found in isolates of Å. |
|
http://www.betamedarts.gr/01-5.htm
|
|
| |
| | Teicoplanin |
| | Welcome to contact us for availability, Certificate of Analysis, Drug Master File (DMF) and FDA approval status. | | | Patented products available for research and development use as permitted under CFR 35 section 271(e)(1) | | | Our Teicoplanin bulk pharmaceutical active is produced by cGMP facility. |
|
http://www.haoruiusa.com/API-R/TeicoplaninSupply.htm
|
|
| |
| | vancomycin and teicoplanin - General Practice Notebook |
| | The information provided herein should not be used for diagnosis or treatment of any medical condition. | | | Oxbridge Solutions Ltd® is an independent company owned by the authors which does not receive income from any other organisation or individual. | | | There are two important differences between vancomycin and teicoplanin; |
|
http://www.gpnotebook.co.uk/cache/-865402865.htm
|
|
| |
| | 31 Performance Evaluation of Three Softwares for Bayesian Predictions of Teicoplanin Pharmacokinetic Parameters: APIS ... |
| | A Bayesian approach was developed to determine the individual pharmacokinetic parameters of teicoplanin from routine clinical data. | | | The population characteristics obtained in this study can also be used for the adaptive control of the teicoplanin dosage in patients with unstable pharmacokinetic parameters due to the therapeutic (extra-corporal purification in renal failure) or to underlying pathology (obesity, anasarca). | | | The individual pharmacokinetic parameters of teicoplanin have been evaluated in 13 subjects by the classical maximum likelihood estimation (MLE) according to a three-compartment model. |
|
http://www.page-meeting.org/page/page95/ABSTRACT/node32.html
|
|
| |
| | INOCULUM |
| | Two courses of teicoplanin alone were prescribed, and 4 patients received vancomycin followed by teicoplanin. | | | All prescriptions of glycopeptide antibiotics during that time were identified by the pharmacy department and the patients' medical and laboratory records were then reviewed. | | | Vancomycin and teicoplanin are glycopeptide antibiotics effective against most Gram-positive organisms and particularly useful when |
|
http://www.usyd.edu.au/~cidm/page/inoculum/jan00.htm
|
|
| |
| | Health Protection Agency - Infections |
| | Acquired glycopeptide resistance in enterococci is associated with transposons and is often transferable. | | | aureus have acquired high-level resistance to vancomycin and teicoplanin mediated by an enterococcal VanA resistance determinant ( 1, 2). | | | Dissociated teicoplanin resistance can also occur in S. |
|
http://www.hpa.org.uk/srmd/div_nsi_armrl/rd.htm
|
|
| |
| | Activities of vancomycin and teicoplanin against penicillin-resistant pneumococci in vitro and in vivo and correlation ... |
| | and human sera were 90% for teicoplanin in both and 25 and 35%, | | | teicoplanin, between 0.1 and 1 mg/kg of body weight for all 10 strains. | | | Fernandez, A., Cabellos, C., Tubau, F., Maiques, J. M., Domenech, A., Ribes, S., Linares, J., Viladrich, P. F., Gudiol, F. Experimental study of teicoplanin, alone and in combination, in the therapy of cephalosporin-resistant pneumococcal meningitis. |
|
http://intl-aac.asm.org/cgi/content/abstract/41/9/1910
|
|
| |
| | Cancer Control Journal: Vancomycin-Resistant Enterococci |
| | Teicoplanin is undergoing clinical trials in the United States, but its status for approval by the Food and Drug Administration is unclear. | | | Pristinamycin is a streptogramin antibiotic aimed at treating Gram-positive infections such as MRSA, and its approval by the Food and Drug Administration also is unclear.[20] Pristinamycin has bactericidal activity by targeting ribosomes and may prove to be of use in VRE infections. | | | The usefulness of teicoplanin may be limited, since it is targeted at the VanB phenotype that has been shown to acquire teicoplanin resistance. |
|
http://www.moffitt.usf.edu/pubs/ccj/v3n1/dept5.html
|
|
| |
| | Clinical Microbiology and Infection Abstract |
| | Although no significant killing was achieved in our kinetic model for any of the strains, regrowth of S. | | | Teicoplanin exerted a concentration-dependent bactericidal effect against S. | | | CFU/mL; (3) studies of the postantibiotic effect (PAE) and the postantibiotic sub-MIC effect (PASME) of teicoplanin; (4) studies of the killing by teicoplanin in an in vitro kinetic model following exposure to simulated human serum pharmacokinetic concentrations (6 mg/kg OD at steady state). |
|
http://www.blackwellpublishing.com/abstract.asp?ref=1198-743X&vid=9&iid=9&aid=5&s=&site=1
|
|
| |
| | The Evans Group Homepage - Home |
| | Teicoplanin and vancomycin are the only two representatives of this family that are used clinically for the treatment of methicillin-resistant Staphylococcus aureus infections and are considered to be the antibiotics of last resort against this pathogen. | | | Teicoplanin ( 1), isolated in 1978 from Actinoplanes teichomyceticus, is a member of a large family of glycopeptide antibiotics which includes vancomycin. | | | The emergence of bacterial strains resistant to treatment by these glycopeptides, and the challenging structural features of these natural products, have prompted extensive investigations into the total syntheses of both vancomycin and teicoplanin ( 1). |
|
http://daecr1.harvard.edu
|
|
| |
| | Technical guide for the detection of Staphylococcus aureus with reduced susceptibility to Glycopeptides |
| | Patients with systemic infections like endocarditis, renal haemodialysis and peritonitis, intensive care patients harbouring MRSA and patients being treated with glycopeptides have increased risk for colonisation or infection with vancomycin intermediate or resistant S. aureus (VISA/VRSA). | | | The interpretation of a positive result is (i) teicoplanin ³ 12 | | | Since these bacteria are also resistant to teicoplanin they can also be termed glycopeptide-intermediate S. aureus (GISA). |
|
http://www.earss.rivm.nl/PAGINA/VISAtechnicalguide.htm
|
|
| |
| | [No title] |
| | Clinical isolates of Enterococcus faecium, Enterococcus faecalis and Staphylococcus epidermidis were studied for their ability to develop resistance by two selection methods, one in broth and one on agar. | | | Comparable results were achieved with the two selection methods. | | | The MICs for enterococci after exposure to vancomycin ranged from 0.5 mg/L to 4 mg/L, and those after exposure to teicoplanin ranged from 0.25 mg/L to 1 mg/L. No significant increases occurred for E. faecalis, whilst two isolates of E. faecium showed increases of up to eight-fold (from 0.125 mg/L to 1 mg/L). |
|
http://www.mednet.gr/infdis/abs041.htm
|
|
|
